Dataset

Balanced prior data

The University of Queensland
Dr Kere Klein (Author) Dr Stefanie Hennig (Author)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.14264/uql.2016.141&rft.title=Balanced prior data&rft.identifier=10.14264/uql.2016.141&rft.publisher=The University of Queensland&rft.description=The dataset used for this study contained the estimated pharmacokinetic (PK) data after intravenous tobramycin administration to children and adults with and without cystic fibrosis, which was previously analysed using a mixed effects modelling approach [1]. Hence, the following two compartment PK parameters: individual clearance (CL), central volume of distribution (V1), distributional clearance (Q) and peripheral volume of distribution (V2) estimates for each patient were available. For the purpose of this study, these individual PK parameter estimates were considered as data.From the whole dataset [1], only patients aged 1-25 years were included which resulted in data from 570 subjects (6.4 to 120 kg, 204 male patients) treated with tobramycin. Included in the Balanced prior data set are: ID (subejct identifier), AGE (age in years), WT (total body weight in kg), CL (clearance of tobramycin from the central compartment), V1 (volume of distribution of the central compartment), Q (intercompartmental clearance), and V2 (volume of distribution of the peripheral compartment). &rft.creator=Dr Kere Klein&rft.creator=Dr Stefanie Hennig&rft.date=2018&rft.relation=https://espace.library.uq.edu.au/view/UQ:282744&rft.relation=https://espace.library.uq.edu.au/view/UQ:290809&rft.relation=https://espace.library.uq.edu.au/view/UQ:384751&rft.relation=https://espace.library.uq.edu.au/view/UQ:410202&rft.relation=https://espace.library.uq.edu.au/view/UQ:371631&rft.relation=https://espace.library.uq.edu.au/view/UQ:383124&rft_subject=Pharmocokinetics&rft_subject=Cystic Fibrosis&rft_subject=Tobramycin&rft_subject=Clinical pharmacology&rft.type=dataset&rft.language=English Access the data

Access:

Other view details

2016,The University of Queensland

Open Access

Creative Commons Attribution (only)

Contact Information

s.hennig@uq.edu.au

Full description

The dataset used for this study contained the estimated pharmacokinetic (PK) data after intravenous tobramycin administration to children and adults with and without cystic fibrosis, which was previously analysed using a mixed effects modelling approach [1]. Hence, the following two compartment PK parameters: individual clearance (CL), central volume of distribution (V1), distributional clearance (Q) and peripheral volume of distribution (V2) estimates for each patient were available. For the purpose of this study, these individual PK parameter estimates were considered as data.From the whole dataset [1], only patients aged 1-25 years were included which resulted in data from 570 subjects (6.4 to 120 kg, 204 male patients) treated with tobramycin. Included in the Balanced prior data set are: ID (subejct identifier), AGE (age in years), WT (total body weight in kg), CL (clearance of tobramycin from the central compartment), V1 (volume of distribution of the central compartment), Q (intercompartmental clearance), and V2 (volume of distribution of the peripheral compartment).

Issued: 2018

Data time period: 2013

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers